Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir

Stanley Zimba, Nyuma Mbewe, Lorraine Chishimba, Mashina Chomba, Deanna Saylor

Research output: Contribution to journalArticlepeer-review

Abstract

In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.

Original languageEnglish (US)
JournalTropical Doctor
DOIs
StateAccepted/In press - 2020

Keywords

  • HIV
  • Tuberculosis
  • dolutegravir
  • immune reconstitution inflammatory syndrome

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir'. Together they form a unique fingerprint.

Cite this